A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
Jingtao Gao(Capital Medical University), Cui Junwei, Yuqing Wu(Capital Medical University), Nyasha Bakare(Janssen (United States)), Y H Liu(Capital Medical University), WU Gui-hui(Center for Tuberculosis Control of Guangdong Province), Nacer Lounis(Johnson Electric (China)), Yanxin Jiang, Gary Mao(Janssen (United States)), Mengqiu Gao(Capital Medical University), Shi Lian(Beijing Tongren Hospital), Huang Zhongfeng, Hua Wang(Anhui Medical University), Wei Sha(Tongji University), Liang Li(Zhejiang University), Huiru An, Xiong Yu, Jian Du(Capital Medical University), Xiujie Li, Ying Zhan(Beijing Normal University), Jin Long, Juan Du(Capital Medical University), Pei Yi(Janssen (United States)), Yu Pang(Beijing Chest Hospital)
Cited by 2
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
Liver diseases: epidemiology, causes, trends and predictions
|Signal Transduction and Targeted Therapy|2025|205
Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling
|Hepatology|2010|157
Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection
|BMC Infectious Diseases|2012|140